ABHD6 Knockout MCF-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population of MCF-7 breast adenocarcinoma cells with targeted disruption of the ABHD6 gene. ABHD6 encodes a serine hydrolase/monoacylglycerol lipase that degrades the endocannabinoid 2-arachidonoylglycerol (2-AG), modulating cannabinoid signaling. This polyclonal pool contains diverse editing events, providing a robust loss-of-function model for population-level studies without clonal selection bias.
The MCF-7 parental line is a widely used epithelial cell model derived from pleural effusion of metastatic mammary carcinoma. It expresses estrogen receptor alpha and retains luminal breast cancer characteristics, making it suitable for investigating hormone responsiveness, tumor progression, and metabolic reprogramming. This background is frequently employed in CRISPR-based functional genomics to interrogate gene function in oncogenic contexts. The ABHD6 knockout in this established background facilitates direct comparison with existing breast cancer literature.
ABHD6 hydrolyzes 2-AG, terminating its signaling at cannabinoid receptors CB1 (CNR1) and CB2 (CNR2). It operates alongside DAGL, MAGL, and FAAH within the endocannabinoid system. ABHD6 is regulated by PPAR??/?? agonists, inflammatory cytokines (TNF??, IL-1??), LPS, insulin signaling, and nutrient availability. Knockout of ABHD6 elevates 2-AG, enhancing CB1/CB2-mediated pathways that target MAPK, AKT, and cyclooxygenase-2 (PTGS2). ABHD6 also interacts with lipid droplets and influences arachidonic acid metabolism and PPAR signaling, linking lipid degradation to inflammation and metabolic control.
In breast cancer, elevated 2-AG resulting from ABHD6 loss may modulate proliferation, migration, and metabolism through cannabinoid receptor engagement. This knockout model thus enables investigation of endocannabinoid-driven oncogenic processes and cross-talk with PPAR, MAPK, and AKT networks. Its relevance extends to obesity-related cancer metabolism and inflammatory tumor microenvironment studies, given the systemic roles of endocannabinoids in energy balance and inflammation.
Research applications include quantifying 2-AG by mass spectrometry, CB1/CB2 activation assays, and Western blotting for MAPK/AKT phosphorylation. Cellular phenotypes can be examined via proliferation (MTT/BrdU), migration (wound healing/transwell), and apoptosis (Annexin V) assays. Transcriptomic analysis via RNA-seq and ABHD6 mRNA validation by RT-qPCR complement protein detection. This knockout tool supports drug discovery for obesity, metabolic syndrome, and neurological disorders, and facilitates mechanistic studies of lipid signaling in breast cancer. For further information, please contact Ascent Research.
